{
  "nctrialId": "HC-1621",
  "title": "A Randomized Open-Label, Active-Controlled Multi-Center Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Spinal Muscular Atrophy",
  "officialTitle": "A Randomized Open-Label, Active-Controlled Multi-Center Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Spinal Muscular Atrophy",
  "sponsor": "Health Canada Research Institute",
  "indication": "Spinal Muscular Atrophy",
  "phase": "Phase 1",
  "fileName": "HC-1621.json",
  "fileSize": 292416,
  "date": "2024-03-16",
  "completionDate": "2026-11-02",
  "drugName": "PSO-602 (phosphodiesterase-4 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Recruiting",
  "description": "This is a randomized open-label, active-controlled multi-center study designed to evaluate the efficacy and safety of PSO-602 (phosphodiesterase-4 inhibitor) in patients with Spinal Muscular Atrophy. The study will enroll approximately 257 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-66 years\n- Confirmed diagnosis of Spinal Muscular Atrophy\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}